References:
Aogi K et al. The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype. Cancer Chemother Pharmacol 2011;67(5):1007-15. Abstract
Brufsky A et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: Subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat 2012;[Epub ahead of print]. Abstract
Corey-Lisle PK et al. Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer. Cancer 2012;118(2):461-8. Abstract
Donoghue M et al. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: Use of a “physician's choice” control arm in a randomized approval trial. Clin Cancer Res 2012;18(6):1496-505. Abstract
Gradishar WJ. The place for eribulin in the treatment of metastatic breast cancer. Curr Oncol Rep 2011;13(1):11-6. Abstract
Gwin K et al. Breast carcinoma with chondroid differentiation: A clinicopathologic study of 21 triple negative (ER-, PR-, Her2/neu-) cases. Int J Surg Pathol 2010;18(1):27-35. Abstract
Metro G et al. Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: Towards optimization of association and schedule. Anticancer Res 2008;28(2B):1245-58. Abstract
Petrelli F et al. Bevacizumab in advanced breast cancer: An opportunity as second-line therapy? Med Oncol 2012;29(1):1-4. Abstract
Robert NJ et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29(10):1252-60. Abstract
Sánchez-Muñoz A et al. Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: Results from a phase II trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer patients. Am J Clin Oncol 2010;33(5):432-7. Abstract
Traina TA et al. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol 2008;26(11):1797-802. Abstract
Verma S et al. Emerging trends in the treatment of triple-negative breast cancer in Canada: A survey. Curr Oncol 2011;18(4):180-90. Abstract